When enfortumab vedotin (now known as Padcev) was initially approved by the FDA in 2019 for use in patients with advanced or metastatic urothelial cancer, it was the first real breakthrough seen in the treatment of bladder cancer in decades. .
Your privacy is our priority
- Hosted on Secure cloud-based hosting
- SOC II Type 1
- HIPAA compliant
- 2FA authentication
- End-to-end data encryption
- Your health data will not be sold or used without your consent. Ever.
